Table 1 Demographic and baseline characteristics.
Variable | Control group n = 27 | Treatment group1 n = 28 | Treatment group2 n = 29 |
|---|---|---|---|
Age (years, mean ± SD) | 45.00 ± 3.17 | 48.00 ± 7.05 | 46.00 ± 7.49 |
Men, n (%) | 19 (70.37%) | 20 (71.43%) | 19 (65.52%) |
History of gout (years, median (range)) | 3.00 (0–9) | 3.00 (0–10) | 3.00 (0–11) |
BMI (kg/m2, mean ± SD) | 32.00 ± 5.07 | 31.07 ± 4.00 | 32.05 ± 5.99 |
Uric acid (pre-treatment) (μmol/L, mean ± SD) | 480.04 ± 98.04 | 470.14 ± 90.12 | 479.97 ± 97.96 |
Onset time, n (%) | |||
 ≤ 24 h | 3 (11.11%) | 4 (14.29%) | 5 (17.24%) |
 24–48 h | 9 (33.33%) | 8 (28.57%) | 8 (27.59%) |
 48–72 h | 15 (55.56%) | 16 (57.14%) | 16 (55.17%) |
Index joint, n (%) | |||
 Metatasophalangeal joint 1 | 4 (14.81%) | 3 (10.71%) | 4 (13.79%) |
 Other foot joints, | 5 (18.52%) | 5 (17.86%) | 9 (31.03%) |
 Ankle | 5 (18.52%) | 6 (21.43%) | 7 (24.14%) |
 Knee | 6 (22.22%) | 9 (32.14%) | 7 (24.14%) |
 Wrist | 1 (3.70%) | 1 (3.57%) | 0 |
 Hand | 2 (7.41%) | 3 (10.71%) | 2 (6.90%) |
 Elbow | 1 (3.70%) | 0 | 0 |
 Multiple joints | 3 (11.11%) | 1 (3.57%) | 0 |
Joint swelling, n (%) | |||
 No swelling | 0 | 2 (7.14%) | 0 |
 Palpable | 6 (22.22%) | 8 (28.57%) | 8 (27.59%) |
 Visible | 6 (22.22%) | 8 (28.57%) | 10 (34.48%) |
 Bulging beyond joint margins | 15 (55.56%) | 10 (35.71%) | 11 (37.93%) |
Activity, n (%) | |||
 No restricted | 0 | 0 | 0 |
 Moderate restricted | 5 (18.52%) | 7 (25.00%) | 9 (31.03%) |
 Significantly restricted | 9 (33.33%) | 11 (39.29%) | 10 (34.48%) |
 Unbearable, cannot take care of themselves | 13 (48.14%) | 10 (35.71%) | 10 (34.48%) |
 Smoke use, n (%) | 5 (18.52%) | 7 (25.00%) | 6 (20.69%) |
 Drink, n (%) | 10 (37.04%) | 11 (39.29%) | 11 (37.93%) |